MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
-0.010
-0.78%
After Hours: 1.280 0 0.00% 16:36 05/19 EDT
OPEN
1.290
PREV CLOSE
1.290
HIGH
1.345
LOW
1.280
VOLUME
366.03K
TURNOVER
--
52 WEEK HIGH
8.92
52 WEEK LOW
1.130
MARKET CAP
55.43M
P/E (TTM)
-1.5304
1D
5D
1M
3M
1Y
5Y
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetin...
PR Newswire · 2d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
--Baird Adjusts Price Target on Cardiff Oncology to $9 From $13, Keeps Outperform Rating
MT Newswires · 05/10 09:18
HC Wainwright lowers Cardiff Oncology PT to $22
HC Wainwright cuts Cardiff Oncology (CRDF) -4% target to $22 from $25 and maintains buy rating. The company reported Q1 earnings and EPS missed estimates for the quarter on May 5.  The company today hit
Seekingalpha · 05/09 17:46
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 05/09 12:02
--HC Wainwright Lowers Cardiff Oncology's Price Target to $22 From $25, Buy Rating Kept
MT Newswires · 05/09 11:28
Cardiff Oncology Q1 EPS $(0.25) Down From $(0.14) YoY, Sales $74.00K Up From $72.00K YoY
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.25) per share. This is a 78.57 percent decrease over losses of $(0.14) per share from the same period last year. The company reported $74.00 thousand in
Benzinga · 05/05 21:43
Cardiff Oncology GAAP EPS of -$0.25 misses by $0.02
Cardiff Oncology press release (NASDAQ:CRDF): Q1 GAAP EPS of -$0.25 misses by $0.02. Royalty Revenue of $0.07M (flat Y/Y). Cash, cash equivalents, and short-term investments of approximately $129.4 million as
Seekingalpha · 05/05 21:00
More
No Data
Learn about the latest financial forecast of CRDF. Analyze the recent business situations of Cardiff Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRDF stock price target is 15.00 with a high estimate of 22.00 and a low estimate of 9.00.
High22.00
Average15.00
Low9.00
Current 1.280
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 106
Institutional Holdings: 22.65M
% Owned: 52.29%
Shares Outstanding: 43.31M
TypeInstitutionsShares
Increased
25
1.54M
New
14
752.75K
Decreased
26
1.21M
Sold Out
21
178.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Rodney Markin
Chief Executive Officer/Director
Mark Erlander
Chief Financial Officer
James Levine
Chief Operating Officer
Vicki Kelemen
Independent Director
James Armitage
Independent Director
John Brancaccio
Independent Director
Mani Mohindru
Independent Director
Gary Pace
Independent Director
Renee Tannenbaum
Independent Director
Lale White
No Data
No Data
About CRDF
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate includes onvansertib , which is a novel polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. The Company's clinical trail includes TROV-052 , a Phase I b/2 open-label clinical trial of onvansertib in combination with standard-of-care low-dose cytarabine (LDAC) , TROV-053 a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone and TROV-054 a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). Its clinical development programs include tumor genomics and biomarker technology to enable assessment of patient response to treatment.

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.